What is it about?
In addition to providing glycaemic control, sodium-glucose co-transporter-2 (SGLT2) inhibitors have transformed the treatment of heart failure by providing cardiovascular and renal advantages. Because of reluctance and worries about adverse effects, clinical adoption is still restricted despite strong data from landmark trials. It is necessary to improve outcomes and improve their integration into cardiovascular treatment by addressing these obstacles through patient awareness, multidisciplinary teamwork, and education.
Featured Image
Photo by Lance Reis on Unsplash
Why is it important?
This study emphasizes that SGLT2 inhibitors, proven to reduce heart failure hospitalizations, cardiovascular mortality, and improve renal outcomes in both diabetic and non-diabetic patients, remain underutilized due to clinical hesitancy, high costs, and systemic limitations. Uniquely, it moves beyond trial efficacy by comparing SGLT2 inhibitors with traditional heart failure therapies, analyzing disparities in use between patient groups, and providing actionable strategies alongside future research directions to improve their integration into routine cardiovascular care.
Perspectives
From a personal perspective, this publication is important because it draws attention to the gap between the proven benefits of SGLT2 inhibitors in heart failure and their limited real-world use, motivating me to advocate for greater clinician awareness, patient education, and system-level changes to ensure more patients can benefit from this transformative therapy.
Manahil Mubeen
Dow University of Health Sciences
Read the Original
This page is a summary of: Enhancing Heart Health: Expanding the Use of SGLT2 Inhibitors in Cardiovascular Disease, iLABMED, June 2025, Tsinghua University Press,
DOI: 10.1002/med4.70014.
You can read the full text:
Contributors
The following have contributed to this page
